Analysis of the presentation today, page-15

Anticipation of more results.

Now that the cap raise is done, they could release a further update today or next week which shows more patients reaching key milestones. I would say that by now a lot more patients will have completed the trial so that if any more data does become available to management, it may provide enough info to draw better conclusions.

Also from now onward we might see the stock climb in anticipation of full phase 2 results which are only really 5 months away.

After the interim results there was always going to be some apprehension from big investors, knowing that a cap raise would need to be done, so hopefully that apprehension will disappear now too.


Don't forget there is potential for a pharma deal after phase 2 results. Positive completion of phase 2 is a major value inflection point in the life of all biotechs.